Meprin A (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Meprin A subunit alpha (MEP1A, UniProt Q16819), expressed in HEK293 cells. Suitable for proteolytic activity assays, inhibitor profiling, substrate identification, and antibody validation.
Expression system
HEK293
Cat. #
REC-MeprinA

In stock

SKU
REC-MeprinA
$498.00

Target Overview

Meprin A subunit alpha (UniProt Q16819; gene MEP1A) is a zinc-dependent metalloendopeptidase of the astacin family (EC 3.4.24.18) encoded by a 746-amino-acid precursor in humans. The mature enzyme is anchored to the membrane and is expressed prominently in the kidney proximal tubule brush border, the intestinal epithelium, and select immune cell populations. As a member of the meprin/A5-protein/receptor tyrosine phosphatase mu (MAM) domain superfamily, it is capable of oligomerising into high-molecular-weight complexes — a property that influences its substrate range and spatial activity at epithelial surfaces. This recombinant is produced in HEK293 mammalian cells, a system that supports the N-glycosylation and disulfide-bond patterns characteristic of the native human protein. Mammalian expression is particularly relevant for Meprin A because its glycan profile affects both catalytic efficiency and protein–protein interactions; studies on renal glycoprotein substrates have highlighted the importance of the glycan context in substrate recognition (Osuka RF et al., iScience, 2025). In the laboratory, this recombinant is used primarily in three contexts. First, it serves as an active enzyme source for fluorogenic or chromogenic peptide-cleavage assays, enabling kinetic characterisation (kcat, Km) against defined substrates. Second, it is used in inhibitor screens and IC50 determinations for small molecules or endogenous inhibitors targeting the astacin active site. Third, it functions as an antigen standard in antibody validation experiments — researchers using Triple Point Biologics' matched MEP1A antibody (SKU: RP-MeprinA) can use this recombinant as a positive-control band on Western blots or as a defined antigen in ELISA or dot-blot formats. The HEK293-expressed form is validated for human Meprin A, with cross-reactivity to mouse, rat, and other mammalian orthologues predicted based on sequence conservation.

Background

Meprin A subunit alpha is a membrane-bound zinc metalloprotease of the astacin family, encoded by MEP1A on chromosome 6p12.3 in humans. It forms homo- or hetero-oligomeric complexes with the closely related Meprin B subunit beta (MEP1B) at epithelial brush-border membranes, particularly in the kidney proximal tubule and small intestine. Its broad substrate repertoire encompasses extracellular matrix components, bioactive peptides, cytokines, and cell-surface proteins — a promiscuity that has made it a subject of sustained interest across several research domains. In renal biology, Meprin A is among the most abundant proteases at the brush-border membrane, and its expression pattern has been investigated in the context of renal function and urinary biomarker studies. Okayama H et al. (J Biochem, 2026) examined the relationship between urinary excretion of nonsulfated HNK-1 glycans and renal dysfunction, a study set that intersects with Meprin A's established role in processing glycoprotein substrates at the tubular surface. Complementing this, Osuka RF et al. (iScience, 2025) characterised selective glycoprotein substrate modification by GnT-V in mouse kidney, work that places Meprin A within a broader framework of how N-glycan remodelling shapes protease substrate availability at renal epithelia. In oncology research, MEP1A expression has been investigated as a tissue marker. De Boeck A et al. (Histopathology, 2026) described a five-marker immunohistochemical panel — including MEP1A, CK17, PAX8, SMAD4, and CDX2 — evaluated for distinguishing ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma. This application underscores the utility of a well-characterised recombinant MEP1A standard for validating immunohistochemical reagents intended for differential diagnostic research. Reproductive biology represents a further area of active investigation: Muccee F (An Acad Bras Cienc, 2025) probed MEP1A as a candidate biomarker associated with post-partum anestrus in buffalo, illustrating that research interest in Meprin A extends across mammalian species and physiological systems. Gastrointestinal and immunological contexts round out the published landscape. Okamura T et al. (Chemosphere, 2025) examined nanoplastic exposure and food allergy in a mouse model that included intestinal protease activity among the measured endpoints, consistent with Meprin A's established prominence at the intestinal brush border. Across all these contexts, the recombinant protein supports in vitro biochemical studies that cannot be addressed with fixed-tissue or antibody-only approaches — including direct activity measurement, substrate cleavage mapping, and inhibitor characterisation. Researchers validating anti-MEP1A antibodies can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-MeprinA), which has been validated for Western blot against human MEP1A.

Applications

  • Fluorogenic or chromogenic peptide substrate cleavage assay (kinetic determination of kcat and Km for astacin-family substrates)
  • Small-molecule inhibitor IC50 determination against the Meprin A active site
  • Western blot positive-control antigen standard paired with TPB anti-MEP1A antibody (SKU: RP-MeprinA)
  • ELISA or dot-blot calibration standard for quantitative MEP1A immunoassay development
  • Substrate identification by mass spectrometry (incubation with candidate matrix or peptide substrates followed by LC-MS/MS)
  • Glycoprotein substrate processing studies examining the influence of N-glycan context on cleavage specificity
  • Immunohistochemistry antibody validation: recombinant antigen used to confirm antibody specificity before use in tissue-section staining panels
  • Biophysical characterisation of Meprin A oligomerisation or protein–protein interactions (e.g., SPR, SEC-MALS)

References

  1. Okayama H et al. Urinary excretion of nonsulfated HNK-1 glycans is associated with renal dysfunction. J Biochem. 2026. doi:10.1093/jb/mvag007. PMID: 41626712.
  2. Osuka RF et al. Selective modification of glycoprotein substrates by GnT-V in mouse kidney. iScience. 2025. doi:10.1016/j.isci.2025.113894. PMID: 41323266.
  3. De Boeck A et al. A 5-marker immunohistochemical panel of CK17, MEP1A, PAX8, SMAD4, and CDX2 to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma. Histopathology. 2026. doi:10.1111/his.70002. PMID: 40970686.
  4. Okamura T et al. Oral exposure to nanoplastics and food allergy in mice fed a normal or high-fat diet. Chemosphere. 2025. doi:10.1016/j.chemosphere.2025.144401. PMID: 40252413.
  5. Muccee F. Probing of MEP1A gene to identify biomarkers associated with post-partum anestrus in buffalo. An Acad Bras Cienc. 2025. doi:10.1590/0001-3765202520230419. PMID: 40105636.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight band should I expect for recombinant Meprin A alpha on SDS-PAGE or Western blot?

The MEP1A precursor is 746 amino acids (~85 kDa predicted), but the HEK293-expressed recombinant runs at approximately 90–100 kDa under denaturing conditions due to N-glycosylation. Under non-reducing conditions, disulfide-linked dimers or higher-order complexes may appear above 150 kDa. If you are using this as a positive control alongside RP-MeprinA, load the reducing lane first to confirm the ~95 kDa glycoprotein band before interpreting non-reduced blots.

What processing form of Meprin A does this recombinant represent — zymogen, prodomain-cleaved, or mature enzyme?

This recombinant is the active, prodomain-processed form of human Meprin A alpha (Q16819). The inhibitory prodomain is removed during HEK293 expression and downstream processing, yielding the mature catalytic enzyme. It is not a zymogen. Because the propeptide is absent, no exogenous activation step (e.g., trypsin treatment) is required prior to activity assays. If your experiment requires a latent zymogen control, this product is not suitable for that purpose.

What substrates does recombinant Meprin A alpha cleave, and are there validated fluorogenic peptide substrates for activity assays?

Meprin A alpha (EC 3.4.24.18) is a zinc-dependent astacin-family endopeptidase with a preference for acidic residues at P1'. Well-validated fluorogenic substrates include the quenched peptide Mca-RPPGFSAFK(Dnp)-OH and OCT (octa-peptide) variants containing acidic cleavage sites. Pro-collagen, IL-18, and fibronectin fragments are documented protein substrates. For initial activity confirmation, 10 µM Mca-RPPGFSAFK(Dnp)-OH in the standard assay buffer at 37 °C is a practical starting point. Monitor fluorescence at Ex/Em 320/405 nm.

What assay buffer should I use for Meprin A (Recombinant) activity assays, and does storage buffer interfere?

Meprin A alpha is active in the pH 6.5–7.5 range; 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 (matching the storage buffer) works well and avoids a dilution-induced buffer switch. Calcium is required for catalytic stability — do not use EDTA or EGTA-containing buffers, as these chelate the active-site zinc and will abolish activity. If your assay buffer is different, dilute the recombinant at least 1:10 into assay buffer immediately before use to minimize glycerol carry-over (final glycerol <1%).

What starting concentration of recombinant Meprin A should I use in a metalloproteinase activity assay?

For fluorogenic peptide cleavage assays (e.g., Mca-RPPGFSAFK(Dnp)-OH at 10 µM), 1–5 nM recombinant Meprin A alpha is a practical starting range; most labs find a linear response between 0.5 and 10 nM enzyme at 37 °C over 30–60 minutes. For substrate Km determination, titrate enzyme at 2 nM with substrate from 1–100 µM. For cell-based or tissue homogenate assays, 10–50 nM is typical to achieve a signal above background within 60 minutes.

How do I factor in IC50 measurements for Meprin A inhibitors using this recombinant?

Use a fixed enzyme concentration of 2–5 nM and a substrate concentration at or below the apparent Km (~20–30 µM for standard quenched peptides) to keep assay conditions in the linear range where IC50 ≈ Ki. Pre-incubate enzyme with inhibitor for 15 minutes at 25 °C before adding substrate. Include a no-inhibitor control and a metal-chelator positive inhibition control (1 mM EDTA) in each plate. Note that the recombinant lacks the propeptide, so inhibitor mechanisms targeting prodomain interactions will not be detected in this format.

Can I use Meprin A (Recombinant) as a positive control for Western blot with the matched RP-MeprinA antibody?

Yes — this is one of the primary design intentions. RP-MeprinA (anti-Meprin A rabbit polyclonal, /anti-meprin-a-rabbit-polyclonal-antibody) is raised and validated in the same laboratory against the same human MEP1A sequence, giving guaranteed epitope compatibility. Load 10–50 ng of recombinant per lane under reducing conditions alongside your cell or tissue lysate. Expect a band at ~90–100 kDa. This lane serves as both a molecular weight reference and an antibody sensitivity control, and confirms that the RP-MeprinA antibody is working before you interpret endogenous signals.

How much recombinant Meprin A should I load for a Western blot positive control lane, and what exposure time is typical?

10–25 ng per lane is sufficient for a clean, well-resolved band at ~90–100 kDa when using RP-MeprinA at a 1:1,000–1:2,000 dilution and standard HRP-secondary detection. Loading 50 ng gives a stronger signal useful during antibody titration. Exposure time on film or digital imager is typically 30–120 seconds at these loads. Over-loading (>100 ng) can cause smearing due to glycoprotein heterogeneity. Run alongside a broad-range MW marker; the glycoprotein band may appear diffuse rather than a sharp single band — this is expected.

What are the storage and handling requirements for Meprin A (Recombinant), and how long is it stable after thawing?

Store at -20 °C in the supplied single-use aliquots (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol). Avoid repeated freeze-thaw cycles — each cycle can reduce metalloproteinase activity by 15–30%. After thawing, keep on ice and use within 4–6 hours; do not refreeze. If same-day use is not possible, the thawed protein can be held at 4 °C for up to 24 hours with acceptable activity retention, but longer storage at 4 °C is not recommended. Purity is >90–95% by SDS-PAGE; endotoxin is <0.1 EU/µg by LAL.

Validation imagery coming soon

Western blot validation figures for REC-MeprinA will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →